Extensive research has demonstrated that SCFAs possessanti-inflammatory properties [65] and inhibit interleukin (IL)-6 and IL-8production through G-protein-coupled receptor (GPR)41/43 activation, thereby,reducing systemic inflammation and improving atherosclerosis [66]. This evidence concerns the gene IL6 and atherosclerosis.